Wearable robotics startup REEV has raised $9.2 million in a funding round that will help the company further develop its mobility assistance solutions for patients with movement disorders.

The funding round was led by Newfund Heka, Polytechnique Ventures and Irdi Capital, with additional support from Techstars and a group of business angels and healthcare operators. Contributors included French soccer player Raphael Varane and knee surgeon Herve Silbert, assembled by Scala Patrimoine, a multi-family office.

“With the support of our partners, we are thrilled to enter the next phase of clinical and industrial development,” REEV Co-Founder/CEO Amaury Ciurana said. “Our technologies, like the DREEVEN motorized orthosis, aim to redefine mobility assistance, transforming lives and reshaping the orthotics industry.”

The company’s technology portfolio comprises two key solutions: REEV SENSE, a motion sensor system that attaches to a patient’s shoe or leg, delivering precise gait analysis; and DREEVEN, a wearable robotics system using electro-hydraulic technology to provide personalized knee assistance.

The funding will support finalizing DREEVEN’s design, conducting a clinical study at the Neuromotor Recovery Lab at Boston University’s Sargent College of Health & Rehabilitation Sciences under the leadership of Dr. Lou Awad, and preparing for U.S. Food and Drug Administration (FDA) trials.

The company is working to address limitations in existing exoskeleton technologies by reducing device weight, lowering costs, and enhancing personalization. The first DREEVEN series is expected to launch in 2026.

“We are proud to continue supporting REEV as they work toward FDA clearance to bring their technology to market in the U.S. This marks a key milestone in improving mobility for neurological patients,” Newfund Partner Anne-Sophie Saint-Martin said.

Recent achievements include:

• A clinical study at Massachusetts Institute of Technology’s Center for Clinical and Translational Research, funded through a grant from the Massachusetts Technology Collaborative’s Massachusetts eHealth Institute (MeHI)
• Production of 100 REEV SENSE commercial units with FDA and CE medical certifications.
• Initial testing of DREEVEN functional units with patients.

REEV is a medtech startup striving to revolutionize mobility assistance. By developing intelligent, lightweight wearable robotics, the company aims to improve quality of life for patients with difficulty walking, helping them regain independence and mobility. Co-founded in 2021 by Ciurana and Chief Technology Officer Dr. Robin Temporelli, the company has grown into a 30-person team, based in Boston, and Toulouse, France.

Newfund is an early-stage venture capital fund that supports entrepreneurs driving disruptive innovation across all sectors, with a particular focus on those with international ambitions. The fund invests seed capital to help initiate international expansion, and continues to support entrepreneurs over the long term through follow-on investments. Through its HEKA thematic fund dedicated to BrainTech, Newfund aims to finance 20 technology startups linked to brain health and its skills. On the subscriber side, Newfund brings together the broadest base of entrepreneurs and family offices in France for an innovation fund.

Established in 2020, Polytechnique Ventures is the Venture Capital fund dedicated to the entrepreneurial ecosystem of École polytechnique. Financed by Alumni, it supports deep tech startups founded by former students, or incubated within the school’s innovation center, or spinoffs from its research laboratories. The fund invests and helps entrepreneurs to develop from inception to post series A steps, focusing on teams with disruptive technologies and a strong game changing industrial strategy.

With €550 million of assets under management in 14 funds, including two evergreen funds, IRDI Capital Investissement is a partner to nearly 200 companies in various sectors. IRDI Capital Investissement has been the leading asset management company in southwest France for 40 years. Based in Toulouse, Montpellier, and Bordeaux, the company provides equity support to regional companies at all stages of development (seed, venture capital, expansion capital/transfer, and rebound). IRDI Capital Investissement conducted this transaction via its IRDINOV3 fund, dedicated to deeptech topics and supported by the Fonds National d’Amorçage 2 (FNA2).